Видео ютуба по тегу Toni Choueiri

ASCOGU25: Toni Choueiri, MD, on LITESPARK003 | Dana-Farber Cancer Institute
ASCOGU25: Toni Choueiri, MD, on LITESPARK003 | Dana-Farber Cancer Institute
PMC Impact - Dr. Toni Choueiri
PMC Impact - Dr. Toni Choueiri
#KCRS19: Toni Choueiri, M.D.
#KCRS19: Toni Choueiri, M.D.
Toni's Legendary Top 10 Papers List!
Toni's Legendary Top 10 Papers List!
Toni Choueiri, MD, Dana-Farber Cancer Institute, Medical Oncology
Toni Choueiri, MD, Dana-Farber Cancer Institute, Medical Oncology
ASCO25: Toni Choueiri, MD, ARC-20 Study | Dana-Farber Cancer Institute
ASCO25: Toni Choueiri, MD, ARC-20 Study | Dana-Farber Cancer Institute
Dr. Choueiri on Atezolizumab Plus Bevacizumab in Non–Clear Cell RCC
Dr. Choueiri on Atezolizumab Plus Bevacizumab in Non–Clear Cell RCC
Cancer Research, Best of 2010s: Toni Choueiri, MD
Cancer Research, Best of 2010s: Toni Choueiri, MD
ASCOGU25: Toni Choueiri MD., on Casdatifan | Dana-Farber Cancer Institute
ASCOGU25: Toni Choueiri MD., on Casdatifan | Dana-Farber Cancer Institute
Dr Toni Choueiri provides an update on kidney cancer management strategies
Dr Toni Choueiri provides an update on kidney cancer management strategies
Dana-Farber Cancer Institute: Toni K. Choueiri, MD (kidney cancer research at ASCO GU21)
Dana-Farber Cancer Institute: Toni K. Choueiri, MD (kidney cancer research at ASCO GU21)
ASCO23: Toni Choueiri, MD | Dana-Farber Cancer Institute
ASCO23: Toni Choueiri, MD | Dana-Farber Cancer Institute
Dr. Toni Choueiri on Nivolumab and Cabozantinib Becoming First-Line Therapies in RCC
Dr. Toni Choueiri on Nivolumab and Cabozantinib Becoming First-Line Therapies in RCC
ESMO22: Toni Choueiri, MD | Dana-Farber Cancer Institute
ESMO22: Toni Choueiri, MD | Dana-Farber Cancer Institute
For physicians: VEGF tyrosine kinase inhibitor treatment risks | Dana-Farber Cancer Institute
For physicians: VEGF tyrosine kinase inhibitor treatment risks | Dana-Farber Cancer Institute
ESMO23: Toni Choueiri, MD LITESPARK-005 | Dana-Farber Cancer Institute
ESMO23: Toni Choueiri, MD LITESPARK-005 | Dana-Farber Cancer Institute